poisar

Stocks · News reference

Immunocore to Present Phase 1/2 Data for Brenetafusp and KIMMTRAK Combination at SITC 2026

Immunocore Holdings plc announced it will present clinical data from its Phase 1/2 trial evaluating brenetafusp in combination with KIMMTRAK for metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IMCR
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

    Immunocore announced it will present Phase 1 data for brenetafusp combined with KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the 2026 SITC Annual Meeting. The presentation will showcase clinical data for the first combination of two T cell engagers in a solid tumor, with poster and oral sessions scheduled for November 6-7, 2026.

    IMCR